New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
November 9, 2009
14:44 EDTDNDN
theflyonthewall.com: Dendreon February volatility at 71, May at 100 into data
Dendreon is recently up 71c to $29.31. DNDN's provenge (a drug that prolongs the lives of advanced prostate-cancer patients) has a PDUFA this spring. DNDN November option implied is at 70, February is at 71, May is at 100; verses its 25-week average of 75, according to Track Data, suggesting larger price movement this spring. :theflyonthewall.com



News For DNDN From The Last 14 Days
Check below for free stories on DNDN the last two weeks.
There are 14 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2012
23:32 EDTDNDN
theflyonthewall.com: Jim Cramer's "Mad Money"

Subscribe for More Information :theflyonthewall.com

February 7, 2012
12:12 EDTDNDN
theflyonthewall.com: Stocks with call strike movement; SHLD DNDN

Subscribe for More Information :theflyonthewall.com
09:24 EDTDNDN
theflyonthewall.com: Pre-market top 5 gainers
The following stocks were the top percentage gainers before the open on solid volume of at least 50,000 shares, trading at over $10. CSTR 18%, AMLN 4.8%, PRGO 4.2%, HGSI 2.3%, DNDN 1%. :theflyonthewall.com
07:16 EDTDNDN
theflyonthewall.com: Dendreon price target raised to $18 from $16 at Canaccord
Canaccord said the negative FDA stance on Amgen's (AMGN) XGEVA de-risks its outlook for Dendreon's (DNDN) Provenge. The firm believes Provenge will occupy a disease treatment setting of newly metastatic disease all alone. Shares are Buy rated. :theflyonthewall.com

February 6, 2012
15:46 EDTDNDN
theflyonthewall.com: Dendreon volume and volatility increases as shares trend higher

Subscribe for More Information :theflyonthewall.com

February 3, 2012
10:30 EDTDNDN
theflyonthewall.com: On The Fly: Analyst Upgrade Summary

Subscribe for More Information :theflyonthewall.com
06:11 EDTDNDN
theflyonthewall.com: Dendreon upgraded to Neutral from Underperform at BofA/Merrill

Subscribe for More Information :theflyonthewall.com

February 1, 2012
13:08 EDTDNDN
theflyonthewall.com: Dendreon CEO change could lead to restructuring, says Cantor
Cantor believes John Johnson's background in marketing and cost structure could lead to a restructuring within Dendreon in 2012. The firm views the CEO transition to Johnson as a good move for Dendreon but keeps a Hold rating on the stock. :theflyonthewall.com
09:27 EDTDNDN
theflyonthewall.com: Pre-market top 5 gainers
The following stocks were the top percentage gainers before the open on solid volume of at least 50,000 shares, trading at over $10. MDVN 19%, STX 14%, WHR 9.2%, FTNT 8.9%, DNDN 5%. :theflyonthewall.com
09:22 EDTDNDN
theflyonthewall.com: Dendreon's new CEO has a history of M&A, says Deutsche Bank
Deutsche Bank said Dendreon's new CEO, John Johnson, has a history of M&A and his fresh perspective might benefit the company's near-term strategy. The firm notes Johnson successfully sold Imclone to Eli Lilly (LLY) and attempted to sell Savient (SVNT). Shares are Buy rated with a $20 price target. :theflyonthewall.com
08:59 EDTDNDN
theflyonthewall.com: Dendreon volatility low as shares rally on succession plan

Subscribe for More Information :theflyonthewall.com
08:17 EDTDNDN
theflyonthewall.com: Dendreon jumps in pre-market trading, resistance at $14.98, then $15.88

Subscribe for More Information :theflyonthewall.com
06:56 EDTDNDN
theflyonthewall.com: Dendreon to host conference call
Conference call to discuss CEO and chairman succession plan will be held on February 1 at 9 am. Webcast Link :theflyonthewall.com
06:35 EDTDNDN
theflyonthewall.com: Dendreon announces CEO and chairman succession plan

Subscribe for More Information :theflyonthewall.com